Data Insights

Risk adjusted net present value: What is the current valuation of MorphoSys's Pelabresib?

Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)....

Net Present Value Model: MorphoSys AG's Pelabresib

Data Insights

Pelabresib by MorphoSys for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Pelabresib is under clinical development by MorphoSys and currently in Phase III for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Pelabresib by MorphoSys for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Pelabresib is under clinical development by MorphoSys and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Pelabresib by MorphoSys for Myelofibrosis: Likelihood of Approval

Pelabresib is under clinical development by MorphoSys and currently in Phase III for Myelofibrosis. According to GlobalData, Phase III drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Myelofibrosis

Data Insights

Tulmimetostat by MorphoSys for Endometrial Cancer: Likelihood of Approval

Tulmimetostat is under clinical development by MorphoSys and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Endometrial Cancer

Data Insights

Tulmimetostat by MorphoSys for Sezary Syndrome: Likelihood of Approval

Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Sezary Syndrome. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Sezary Syndrome

Data Insights

Tulmimetostat by MorphoSys for Mycosis Fungoides: Likelihood of Approval

Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Mycosis Fungoides. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Mycosis Fungoides

Data Insights

Tulmimetostat by MorphoSys for Fallopian Tube Cancer: Likelihood of Approval

Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Fallopian Tube Cancer

Data Insights

Tulmimetostat by MorphoSys for Peritoneal Cancer: Likelihood of Approval

Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Peritoneal Cancer

Data Insights

Pelabresib by MorphoSys for Essential Thrombocythemia: Likelihood of Approval

Pelabresib is under clinical development by MorphoSys and currently in Phase II for Essential Thrombocythemia. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Essential Thrombocythemia

Data Insights

Felzartamab by MorphoSys for Systemic Lupus Erythematosus: Likelihood of Approval

Felzartamab is under clinical development by MorphoSys and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Felzartamab in Systemic Lupus Erythematosus

Data Insights

Pelabresib by MorphoSys for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval

Pelabresib is under clinical development by MorphoSys and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)

Data Insights

Tafasitamab by MorphoSys for Primary CNS Lymphoma: Likelihood of Approval

Tafasitamab is under clinical development by MorphoSys and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...

Data Insights

Tafasitamab by MorphoSys for Leukemia: Likelihood of Approval

Tafasitamab is under clinical development by MorphoSys and currently in Phase II for Leukemia. According to GlobalData, Phase II drugs...